AUS
NZ
UK
CA
USA
IND
Pilbara Minerals Limited
The West Perth-based Pilbara Minerals Limited (ASX:PLS) explores and evaluates mineral resources in Australia. The Group has a large market cap of ADU 1.25 billion to date. At the end of the trading session on March 18th, 2019, the PLS stock price closed at AUD 0.715, with no intra-day change, and ~ 2.96 million shares traded.
Recently the company announced to have conditionally exercised its option to enter into an incorporated joint venture (JV) with POSCO, for up to 30% participation, for the development of a downstream lithium chemical conversion facility in Gwangyang Free Economic Zone in South Korea.
Besides, the Group also released its interim financial report for the half-year ended December 31st, 2018, posting the Groupâs consolidated loss after tax for the period at ~ $ 11.9 million as compared to the loss after tax of $ 9.97 million recorded in the prior corresponding period (pcp). After extensive net cash outflows from operating ($ 7.08 million) and investing ($ 44.95 million) activities along with cash inflows of $ 2.39 million from financing activities, the Groupâs net cash in hand amounted to $ 70.26 million.
AVZ Minerals Limited
AVZ Minerals Limited (ASX:AVZ), based in Mount Hawthorn, is a mineral exploration company with key operations in central Africa. On March 18th, 2019, the AVZ stock price closed trading at AUD 0.044, up 7.317%, by AUD 0.003 and ~ 23.22 million shares traded at the end of the market session. To date, AVZ has a market cap of AUD 93.61 million to date.
On the same day, the company announced that its strategic shareholder Zhejiang Huayou Cobalt Co., Ltd, through its group company Huayou International Mining Limited, increased its stake in AVZ to 9.49% after purchasing additional shares on the market. Besides, AVZ also released its financial results for the half-year ended December 31st, 2018, with the loss after income tax at $ 2.74 million and the net assets valuation at ~ $ 64.47 million. At the end of the period, the net cash stood at $ 909.5k.
Earlier in March, AVZ also received the results form the final 2 of 6 reconnaissance drill holes under the Mineral Resource drilling at the Carriere de lâEste prospect confirming presence of further extensive high-grade spodumene lithium mineralisation including 68.0m* @ 2.0% Li2O & 858ppm Sn in hole CD18DD006.
Emerge Gaming Limited
The Subiaco, Australia-based Emerge Gaming Limited (ASX:EM1) offers an online platform globally that enables users to engage in skill-based gaming competitions in e-sports, including peer-to-peer matches and tournaments. To date, the company has a market cap of AUD 16.45 million. With the end of trading on March 18th, 2019, the EM1 stock price closed at AUD 0.030, up 7.14%, by AUD 0.002 and approximately 54.2 million shares traded.
On the same day, Emerge Gaming reverted ASX on its price query lodged on March 15th, 2019, regarding the change in the share price of EM1 from a low of AUD 0.022 to an intra-day high of AUD 0.029, along with a significant increase in the volume of EM1âs securities traded over the past few days. The company believes that the announcement (February 19th, 2019) concerning the launch and strategy of ArcadeX Media Gaming Platform in Australia and other Tier 1 countries could be one possible explanation.
As per half-year results for the six months to December 31st, 2018, Emerge Gaming recorded revenue from ordinary activities at $ 129,615, up 11171% on $ 1,150 in the pcp. Besides, the loss after tax attributable to members stood at $ 887.8k, up 45%, on the loss after tax of $ 610.6k recorded in pcp.
Resapp Health Limited
The Brisbane, Australia-based Resapp Health Limited (ASX:RAP), established in 2014, is engaged in the development and commercialisation of the smartphone applications for the diagnosis and management of respiratory diseases. Currently, the company has a market cap of AUD 69.25 million, At the end of the trading session on March 18th, the RAP stock price closed at AUD 0.085, down 3.409%, by AUD 0.003 and ~ 1.66 shares traded.
Recently, the company posted top-line results for primary upper respiratory tract disease (URTD) from its SMARTCOUGH-C-2 study, which was conducted to evaluate the ResAppDx application to diagnose childhood acute respiratory disease. Prior to that, Resapp also received approval from AusIndustry for its request for an Advanced/Overseas Finding in respect to clinical study expenditure associated with its USbased paediatric and adult clinical studies for the diagnosis of respiratory disease using cough sounds.
For the half-year ended December 31st, 2018, the company recorded revenue from ordinary activities at $ 34,742, down 38.665 on pcp along with a net loss for the period attributable to members at $ 3.33 million, up 4.5 % on pcp. The net cash and cash equivalents as of December 31st, 2018 stood at $ 6.81 million.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
